FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2994162021> ?p ?o ?g. }

• W2994162021 endingPage "118910" @default.
• W2994162021 startingPage "118910" @default.
• W2994162021 abstract "During the pharmaceutical development of pregabalin extended-release tablets, an unknown degradant at a relative retention time (RRT) of 11.7 was observed and its nominal amount exceeded the ICH identification threshold in an accelerated stability study. The aim of this study is to identify the structure and investigate the formation mechanism of this impurity for the purpose of developing a chemically stable pharmaceutical product. By utilizing multi-stage LC-MS analysis in conjunction with mechanism-based stress study, the structure of the RRT 11.7 impurity was rapidly identified as a dimeric degradant that is caused by dimerization of two pregabalin molecules with a methylene bridging the two pregabalin moieties. The structure of the dimer was confirmed by 1D and 2D NMR measurement. The formation pathway of the dimeric degradant was also inferred from the mechanism-based stress study, which implicated that the bridging methylene could originate from formaldehyde which might be the culprit that triggers the dimerization in the first place. The subsequent API-excipients compatibility study indicated that the degradant was indeed formed in the compatibility experiments between pregabalin API and two polymeric excipients (PEO and PVPP) that are known to contain residual formaldehyde, but only in the co-presence of another excipient, colloidal silicon dioxide (SiO2). The kinetic behavior of the degradant formation was also investigated and two kinetic models were utilized based on the Arrhenius and Eyring equations, respectively, to calculate the activation energy (Ea) as well as the enthalpy of activation (△H‡), entropy of activation (△S‡), and Gibbs free energy (△G‡) of the degradation reaction. The results of this study would be useful for the understanding of similar dimeric degradant formation in finished products of drug substances containing primary or secondary amine moieties." @default.
• W2994162021 created "2019-12-13" @default.
• W2994162021 creator A5004437037 @default.
• W2994162021 creator A5017165462 @default.
• W2994162021 creator A5021671287 @default.
• W2994162021 creator A5022597016 @default.
• W2994162021 creator A5032398690 @default.
• W2994162021 creator A5038851564 @default.
• W2994162021 creator A5044367029 @default.
• W2994162021 creator A5049459192 @default.
• W2994162021 creator A5052024256 @default.
• W2994162021 creator A5053936942 @default.
• W2994162021 creator A5055213472 @default.
• W2994162021 creator A5063465957 @default.
• W2994162021 creator A5074497471 @default.
• W2994162021 creator A5076819745 @default.
• W2994162021 date "2020-02-01" @default.
• W2994162021 modified "2023-10-16" @default.
• W2994162021 title "Structure elucidation and formation mechanistic study of a methylene-bridged pregabalin dimeric degradant in pregabalin extended-release tablets" @default.
• W2994162021 cites W1153130334 @default.
• W2994162021 cites W1567555575 @default.
• W2994162021 cites W1965772289 @default.
• W2994162021 cites W1975449496 @default.
• W2994162021 cites W1986661060 @default.
• W2994162021 cites W1991828360 @default.
• W2994162021 cites W1996576937 @default.
• W2994162021 cites W2025790999 @default.
• W2994162021 cites W2049150132 @default.
• W2994162021 cites W2054260401 @default.
• W2994162021 cites W2054456522 @default.
• W2994162021 cites W2063669407 @default.
• W2994162021 cites W2068602147 @default.
• W2994162021 cites W2073236381 @default.
• W2994162021 cites W2081974022 @default.
• W2994162021 cites W2133039415 @default.
• W2994162021 cites W2144217084 @default.
• W2994162021 cites W2144873009 @default.
• W2994162021 cites W2165209946 @default.
• W2994162021 cites W2425308730 @default.
• W2994162021 cites W2593215347 @default.
• W2994162021 cites W2770930683 @default.
• W2994162021 cites W2912811834 @default.
• W2994162021 cites W2963668928 @default.
• W2994162021 doi "https://doi.org/10.1016/j.ijpharm.2019.118910" @default.
• W2994162021 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31805310" @default.
• W2994162021 hasPublicationYear "2020" @default.
• W2994162021 type Work @default.
• W2994162021 sameAs 2994162021 @default.
• W2994162021 citedByCount "5" @default.
• W2994162021 countsByYear W29941620212020 @default.
• W2994162021 countsByYear W29941620212021 @default.
• W2994162021 countsByYear W29941620212022 @default.
• W2994162021 countsByYear W29941620212023 @default.
• W2994162021 crossrefType "journal-article" @default.
• W2994162021 hasAuthorship W2994162021A5004437037 @default.
• W2994162021 hasAuthorship W2994162021A5017165462 @default.
• W2994162021 hasAuthorship W2994162021A5021671287 @default.
• W2994162021 hasAuthorship W2994162021A5022597016 @default.
• W2994162021 hasAuthorship W2994162021A5032398690 @default.
• W2994162021 hasAuthorship W2994162021A5038851564 @default.
• W2994162021 hasAuthorship W2994162021A5044367029 @default.
• W2994162021 hasAuthorship W2994162021A5049459192 @default.
• W2994162021 hasAuthorship W2994162021A5052024256 @default.
• W2994162021 hasAuthorship W2994162021A5053936942 @default.
• W2994162021 hasAuthorship W2994162021A5055213472 @default.
• W2994162021 hasAuthorship W2994162021A5063465957 @default.
• W2994162021 hasAuthorship W2994162021A5074497471 @default.
• W2994162021 hasAuthorship W2994162021A5076819745 @default.
• W2994162021 hasConcept C15744967 @default.
• W2994162021 hasConcept C178790620 @default.
• W2994162021 hasConcept C185592680 @default.
• W2994162021 hasConcept C2776380872 @default.
• W2994162021 hasConcept C2776468701 @default.
• W2994162021 hasConcept C2777454769 @default.
• W2994162021 hasConcept C2779546866 @default.
• W2994162021 hasConcept C542102704 @default.
• W2994162021 hasConcept C71240020 @default.
• W2994162021 hasConceptScore W2994162021C15744967 @default.
• W2994162021 hasConceptScore W2994162021C178790620 @default.
• W2994162021 hasConceptScore W2994162021C185592680 @default.
• W2994162021 hasConceptScore W2994162021C2776380872 @default.
• W2994162021 hasConceptScore W2994162021C2776468701 @default.
• W2994162021 hasConceptScore W2994162021C2777454769 @default.
• W2994162021 hasConceptScore W2994162021C2779546866 @default.
• W2994162021 hasConceptScore W2994162021C542102704 @default.
• W2994162021 hasConceptScore W2994162021C71240020 @default.
• W2994162021 hasLocation W29941620211 @default.
• W2994162021 hasLocation W29941620212 @default.
• W2994162021 hasOpenAccess W2994162021 @default.
• W2994162021 hasPrimaryLocation W29941620211 @default.
• W2994162021 hasRelatedWork W1982749349 @default.
• W2994162021 hasRelatedWork W2056792255 @default.
• W2994162021 hasRelatedWork W2175561168 @default.
• W2994162021 hasRelatedWork W2331077834 @default.
• W2994162021 hasRelatedWork W2338996536 @default.
• W2994162021 hasRelatedWork W2396526554 @default.
• W2994162021 hasRelatedWork W2950036499 @default.
• W2994162021 hasRelatedWork W2950038481 @default.

• next